Denmark is often described as a “DRG country”. That is technically true but strategically misleading.

On the surface, the Danish DRG system looks familiar: national groupers, published tariffs, annual updates, and structured activity classification. For MedTech, diagnostics, biotech and digital health companies, this similarity can create a false sense of confidence — and market access strategies that fail quickly.

Denmark’s DRGs are not a volume-driven payment engine (as in Germany) and they are not routinely supplemented by add-ons and carve-outs to monetise innovation (as in France). Instead, Danish DRGs function primarily as a planning, benchmarking and cost-transparency language inside a tax-funded healthcare system where real financial control sits with the five regions and their fixed budgets.

If you approach Denmark expecting tariff uplift, new DRG creation, or “reimbursement wins” in the classic sense, you will likely stall. If you approach Denmark as a disciplined system that rewards capacity release, pathway stability, and operational predictability, you can unlock something more valuable than early monetisation: credibility that travels across the Nordics, the Netherlands, Germany, and beyond.

This article explains how Denmark’s DRG system actually works — and how innovators should engage with it to secure adoption and market access.

How reimbursement really works in Denmark’s DRG system

The Danish DRG system is best understood as an activity measurement and steering framework, not a per-case payment mechanism in the commercial sense.

In practice, Denmark runs a hybrid model:

Hospitals deliver care under regional budget envelopes
Activity is recorded in DRG and DAGS units
DRGs convert clinical activity into comparable “financial units” for planning, benchmarking and control
But activity does not automatically convert into incremental revenue for hospitals

This has immediate consequences for innovators:

Hospitals do not “earn more” by doing more DRG-coded cases
Tariffs are conservative by design, reflecting historical average costs
Carve-outs and add-ons are structurally resisted because they undermine comparability and create long-term budget liabilities

So “accessing DRGs” in Denmark rarely means negotiating a tariff or chasing a new code. It means proving where your technology sits in the pathway, and whether it helps the system run more predictably under constraint.

What the Danish DRG system is and what it is not

What Danish DRGs are used for

Danish DRGs are primarily used to:

Translate hospital activity into comparable units
Enabling system-wide visibility across heterogeneous care.
Support regional planning and budgeting
Regions forecast expected activity (in DRG/DAGS units) to plan capacity and spend.
Enable productivity and cost benchmarking
National average-cost tariffs make cross-hospital comparisons possible.
Provide transparent, empirical cost signals
DRG tariffs describe observed reality rather than aspirational pricing.

What Danish DRGs are not designed to do

Danish DRGs are not intended to:

Maximise hospital income
Incentivise volume growth
Provide rapid reimbursement pathways for innovation
Act as a negotiation instrument for supplier pricing
Serve as an authorisation tool determining which hospitals may deliver complex care

In Denmark, DRGs are not levers to be pulled. They are constraints to be understood.

Who pays, who decides, and where adoption actually happens

Many market access strategies fail in Denmark because they target the wrong decision-maker.

The State: rules and transparency not purchasing

National bodies define and publish:

DRG/DAGS structures and grouping logic
Tariff tables and documentation
Classification rules and updates

But national actors do not purchase hospital care and generally do not negotiate supplier adoption.

The Regions: where budget accountability sits

Denmark’s five regions are the true fiscal decision-makers. They:

Own and operate public hospitals
Receive global budgets
Carry political accountability for waiting times, capacity and stability
Use DRG-weighted activity to plan, monitor and manage delivery

Hospitals: operational fit matters more than “reimbursement”

Hospital leadership evaluates innovation primarily through:

Does it stabilise the pathway?
Does it release capacity (beds, staff time, theatre slots, diagnostics throughput)?
Does it reduce variance and escalation?
Does it improve flow predictability?

A product can be “technically reimbursed” and still fail if it increases operational volatility. Conversely, a solution can be cost-neutral and succeed if it improves throughput and planning reliability.

DRG tariffs in Denmark: why they are conservative (and why that’s rational)

Danish DRG tariffs are empirically grounded: they are built from observed cost accounts linked to recorded patient activity. They reflect historical national average costs, not forward-looking “innovation prices”.

This is exactly why tariffs can look “flat”:

Updates are typically conservative and budget-neutral
Averaging and lagged cost data dampen volatility
National aggregation avoids rewarding local high performers with higher “prices”
Structural tariff growth would create long-term liabilities under fixed regional budgets

For innovators, the key point is simple:

Tariffs are context, not upside.
Denmark expects improvement to be demonstrated within the envelope by changing how the pathway behaves, not by pricing innovation on top.

Denmark vs Germany, France and the Netherlands: the mental model that prevents failure

A practical shorthand:

Germany uses DRGs to pay hospitals (activity → revenue)
France uses DRGs plus add-ons to price innovation
The Netherlands uses DRGs to enable selective contracting and structural control
Denmark uses DRGs to understand and manage the system

Denmark’s DRGs describe reality; they are not designed to reshape behaviour through price signals.

Is Denmark an “aggregator” system? Yes but not the way most suppliers mean

Denmark’s DRGs bundle episodes of care as a structural cost aggregator. Diagnostics, procedures, ward time, theatre use, ICU days, support services and overheads are generally assumed to be “inside the episode” unless explicitly carved out.

This is why Denmark strongly resists carve-outs and add-ons: fragmentation breaks comparability and makes long-term cost control harder.

For diagnostics and digital health in particular, this changes everything:

If you are not paid per test or per interaction, you win by proving your tool changes the pathway: fewer admissions, shorter stays, fewer escalations, fewer repeat investigations, better flow.

Where innovation creates real leverage in Denmark

Denmark rewards technologies that make the system easier to run. Four levers consistently resonate:

Timing: bringing decisions forward
Earlier certainty → shorter stays, fewer precautionary admissions, fewer cascades.
Variance reduction: controlling the outliers
Denmark cares deeply about escalation events and long-stay outliers that destabilise planning.
Capacity release: solving the real constraint
Beds, staffing and throughput are often more binding than money.
Pathway simplification: reducing system noise
Fewer steps, fewer handoffs, clearer decision logic, less operational friction.

In Denmark, “clever” often beats “cheap”.

Evidence, pilots and why adoption often comes before reimbursement change

Denmark frequently pilots technologies without changing DRGs or tariffs. That is not incoherent — it is disciplined.

Pilots in Denmark are primarily operational learning exercises:

Does it work in Danish workflow reality?
Does it reduce staff burden, escalation, length of stay, or pathway volatility?
Does it improve planning reliability?

Evidence that tends to matter most:

Length of stay and discharge timing
Escalation rates (ICU, complications, repeat workups)
Avoided admissions / readmissions
Workflow and staff time impacts
Registry-aligned outcomes that decision-makers can validate

Denmark’s registry infrastructure makes over-claiming risky and specificity valuable. If you design pilots aligned to existing variables, you reduce friction and increase credibility.

Practical market access approach: what to do (and what to stop doing)

Do this in Denmark

Map the current pathway and identify 1–2 pressure points you materially improve
Use DRGs as a system language (context and comparability), not a “target”
Build a pilot that demonstrates capacity release and variance reduction quickly
Align endpoints to existing Danish data structures wherever possible
Engage regional and hospital leadership with an operational story they recognise

Stop doing this

Chasing DRG uplift as the primary commercial objective
Treating new DRG creation as an “innovation funding route”
Importing a German or French reimbursement playbook
Overbuilding economic models detached from Danish operational reality

Frequently asked questions about Denmark’s DRG system

Is Denmark a DRG-based hospital reimbursement system?

Denmark uses DRGs nationally, but primarily for planning, benchmarking and transparency inside regional budgets — not as an activity-to-revenue engine.

Do Danish hospitals get paid per DRG case?

Not in the commercial sense. DRG activity is measured, monitored and compared, but funding is governed by regional budget frameworks.

Can we apply for a new DRG code in Denmark?

DRG updates occur, but they reflect established patterns of care and classification maturity they are rarely a primary route to monetising innovation.

Why are Danish DRG tariffs conservative?

They are empirically cost-based and budget-neutral by design, reflecting historical national average costs rather than innovation pricing.

Why doesn’t Denmark use add-ons or carve-outs for innovation?

Because carve-outs reduce comparability and create long-term structural liabilities under fixed regional budgets.

What evidence matters most for adoption?

Pragmatic, real-world, pathway-specific evidence: length of stay, escalation, admissions avoided, workflow effects, and registry-aligned outcomes.

Is Denmark “hard” for innovation?

Denmark is disciplined, not hostile. Technologies that stabilise pathways and release capacity can achieve adoption even without tariff change.

Denmark is not designed to reward innovation through reimbursement mechanics. It is designed to keep a tax-funded system stable under constraint.

For many innovators, Denmark is best approached as a validation and credibility market:

If your technology works in Denmark under fixed budgets, tight capacity and disciplined governance — that evidence often travels across Northern Europe.

References

Danish Health Data Authority (Sundhedsdatastyrelsen) — DRG tariffs and documentation
https://sundhedsdatastyrelsen.dk/data-og-registre/sundhedsoekonomi/drg/drg-takster

Danish Health Data Authority — health economics / tariff system documentation (Takstsystem context)
https://sundhedsdatastyrelsen.dk/da/registre-og-services/om-sundhedsdata/sundhedsoekonomi

Danish National Patient Registry (Landspatientregisteret)
https://sundhedsdatastyrelsen.dk/da/registre-og-services/om-de-nationale-sundhedsregistre/sygdomme-laegemidler-og-behandlinger/landspatientregisteret

OECD — Diagnosis-related groups overview and international context
https://www.oecd.org/health/health-systems/diagnosis-related-groups.htm

Nordic Council of Ministers — Health and welfare (Nordic system context)
https://www.norden.org/en/theme/health-and-welfare

Hamburg Centre for Health Economics — DRG payment reforms (international perspective, working paper)
https://www.hche.uni-hamburg.de/dokumente/research-papers/rp-28-drg-payment-reforms-wp-note.pdf

Denmark DRG Reimbursement Explained: How to Secure Market Access